Clinical trial
A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
NCT02657005 is registered in ClinicalTrials.gov with Oncternal Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
- Lead sponsor
- Oncternal Therapeutics, Inc
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- August 31, 2016
- Completion date
- June 30, 2022
- Enrollment
- 85 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.